Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents

References

• Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, Anastasakou E, Kotsi P, Karafoulidou A, Stergiou GS. 2009. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol. 54:163–168.
   PubMed Web of Science ®Google Scholar
• Aihara H, Sato A, Takeyasu N, Nishina H, Hoshi T, Akiyama D, Kakefuda Y, Watabe H, Aonuma K. 2012. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry. Catheter Cardiovasc Interv. 80:556–563.
   PubMed Web of Science ®Google Scholar
• Al-Shammari M, Shah S, Maklad M, Yoo JW, Makar RS. 2017. Do proton pump inhibitors really increase cardiovascular risk? A systematic review and meta-analyses of existing literature. Am J Gastroenterol. 112: S666–S667.
   PubMed Web of Science ®Google Scholar
• Andersson T, Morrison D, Nagy P, Pisupati J, Schettler J, Warner TD. 2012. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Am J Cardiovasc Drugs. 12:217–224.
   PubMed Web of Science ®Google Scholar
• Angiolillo D, Datto C, Raines S, Yeomans N. 2014. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies. J Thromb Thrombolysis. 38:11–23.
   PubMed Web of Science ®Google Scholar
• Antunes AGG, Vaz A, Queiros P, Gago T, Roseira J, Santos Peixe BM, Guerreiro H. 2016. Continuous proton pump inhibitor therapy increases the risk of bacterial infection in cirrhotic patients. United Eur Gastroenterol J. 4:A166.
   Google Scholar
• Arana A, Johannes CB, McQuay LJ, Varas-Lorenzo C, Fife D, Rothman KJ. 2015. Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case–control study. Drug Saf. 38:1187–1199.
   PubMed Web of Science ®Google Scholar
• Asim Syed IA, Abbas Naqvi SH. 2016. Proton pump inhibitors use; beware of side-effects. J Pak Med Assoc. 66:1314–1318.
   PubMedGoogle Scholar
• Banerjee S, Weideman RA, Weideman MW, Little BB, Kelly KC, Gunter JT, Tortorice KL, Shank M, Cryer B, Reilly RF, et al. 2011. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 107:871–878.
   PubMed Web of Science ®Google Scholar
• Bang U, Bendtsen F. 2018. The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death. J Hepatol. 68:S812–S813.
   Web of Science ®Google Scholar
• Bell EJ, St Sauver JL, Roger VL, Larson NB, Liu H, Wang L, Turner S, Bielinski SJ. 2017. Proton pump inhibitor use is positively associated with incidence of cardiovascular disease. Circ Conf Am Hear Assoc Epidemiol Prev Cardiometabolic Heal. 135:253.
   Google Scholar
• Bettinger D, Martin D, Rieg S, Schultheiss M, Buettner N, Thimme R, Boettler T. 2018. Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess. Aliment Pharmacol Ther. 47:801–808.
   PubMed Web of Science ®Google Scholar
• Bhatt D, Contant C, Cohen M, Lanas A, Schnitzer T, Shook T, Lapuerta P, Goldsmith M, Laine L, Scirica B. 2010. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 363:1909–1917.
   PubMed Web of Science ®Google Scholar
• Bhatt D, Laine L, Cannon P. 2011. Clopidogrel with or without omeprazole in coronary disease. N Engl J Med. 364:682–683.
   Google Scholar
• Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. 2012. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 32:809–818.
   PubMed Web of Science ®Google Scholar
• Bo¨ger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. 2009. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 119:1592–1600.
   PubMed Web of Science ®Google Scholar
• Böger RH, Zoccali C. 2003. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl. 4:23–28.
   PubMed Web of Science ®Google Scholar
• Burkard T, Kaiser CA, Brunner-La Rocca H, Osswald S, Pfisterer ME, Jeger RV, Investigators B. 2012. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med. 271:257–263.
   PubMed Web of Science ®Google Scholar
• Caffrey AR, Timbrook TT, Sakoulas G, LaPlante KL. 2016. Do proton pump inhibitors impact clinical outcomes in Staphylococcus aureus bacteremia? Pharmacoepidemiol Drug Saf. 25:468–469.
   Web of Science ®Google Scholar
• Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FYB, El-Hayek G, Nadkarni GN, Gili S, Iannaccone M, Konstantinidis I, et al. 2015. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Hear. 2:e000248.
   PubMed Web of Science ®Google Scholar
• Chan FKL, Wong VWS, Suen BY, Wu JCY, Ching JYL, Hung LCT, Hui AJ, Leung VKS, Lee VWY, Lai LH, et al. 2007. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 369:1621–1626.
   PubMed Web of Science ®Google Scholar
• Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, Hansen PR, Madsen JK, Kober L, Torp-Pedersen C. 2010. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 153:378–386.
   PubMed Web of Science ®Google Scholar
• Charlot M, Grove G, Hansen P, Olesen J, Ahlehoff O, Selmer C, Lindhardsen J, Madsen J, Kober L, Torp-Pedersen C. 2011. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 342:d2690.
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Lee K-T, Lee CT-C, Lai W-T, Huang Y-B. 2014. Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. Int J Stroke. 9:580–590.
   PubMed Web of Science ®Google Scholar
• Ching G, Li D, Baker W, Hohl P, Mather J, McKay R, Lundbye J. 2012. Major adverse cardiac events among postpercutaneous coronary intervention patients on clopidogrel and proton pump inhibiors. Conn Med. 76:205–211.
   PubMedGoogle Scholar
• Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R, Maruyama H, Hirose T, et al. 2012. Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J. 76:71–78.
   PubMed Web of Science ®Google Scholar
• CIOMS. 2016. Evidence Synthesis and Meta-Analysis for Drug Safety. Geneva, Switzerland: Council for International Organizations of Medical Sciences.
   Google Scholar
• Cooke JP. 2004. Asymmetrical dimethylarginine: the Uber marker? Circulation. 109:1813–1818.
   PubMed Web of Science ®Google Scholar
• Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. 1992. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ. 304:143–147.
   PubMedGoogle Scholar
• Daskalopoulou SS, Delaney JAC, Filion KB, Brophy JM, Mayo NE, Suissa S. 2008. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 29:2083–2091.
   PubMed Web of Science ®Google Scholar
• de Francisco ALM, Varas J, Ramos R, Merello JI, Canaud B, Stuard S, Pascual J, Aljama P, Aljama P, Canaud B, et al. 2018. Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. Kidney Int Rep. 3:374–384.
   PubMed Web of Science ®Google Scholar
• Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, Cresci S. 2015. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 15:20–25.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials. 7:177–188.
   PubMed Web of Science ®Google Scholar
• Douglas IJ, Evans SJW, Hingorani AD, Grosso AM, Timmis A, Hemingway H, Smeeth L. 2012. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. 345:e4388.
   PubMedGoogle Scholar
• Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. 2015. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther. 41:459–466.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2009. Public statement on possible interaction between clopidogrel and proton pump inhibitors. 2017.
   Google Scholar
• Evanchan J, Donnally MR, Binkley P, Mazzaferri E. 2010. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 33:168–171.
   PubMed Web of Science ®Google Scholar
• Evidence Partners. Distiller SR. www.evidencepartners.com
   Google Scholar
• Faillie JL. 2015. Indication bias or protopathic bias? Br J Clin Pharmacol. 80:779–780.
   PubMed Web of Science ®Google Scholar
• Fayer Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ. 2006. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 34:600–607.
   PubMed Web of Science ®Google Scholar
• FDA. 2009. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix).
   Google Scholar
• Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonso J, Jaeschke R, Schünemann HJ, Permanyer-Miralda G, et al. 2007. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 334:786–788.
   PubMed Web of Science ®Google Scholar
• Focks J, Brouwer M, Van Oijen M, Lanas A, Bhatt D, Verheugt F. 2013. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome − a systematic review. Heart. 99:520–527.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Salmasian H, Friedman C, Abrams JA. 2013. Proton pump inhibitors and risk for recurrent clostridium difficile infection among inpatients. Am J Gastroenterol. 108:1794–1801.
   PubMed Web of Science ®Google Scholar
• Gaglia MA, Torguson R, Hanna N, Gonzalez MA, Collins SD, Syed AI, Ben-dor I, Maluenda G, Delhaye C, Wakabayashi K, et al. 2010. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol. 105:833–838.
   PubMed Web of Science ®Google Scholar
• Galante C, Santos V, da Cunha G. 2012. Assessment of the use of clopidogrel associated with gastroprotective medications in outpatients. Farm Hosp. 36:216–219.
   PubMedGoogle Scholar
• Gao Q-P, Sun YY-X, Sun YY-X, Wang L-F, Fu L. 2009. Early use of omeprazole benefits patients with acute myocardial infarction. J Thromb Thrombolysis. 28:282–287.
   PubMed Web of Science ®Google Scholar
• Gardezi A, Tibbats C, Aslam U, Chase L, Fahmy H. 2018. Use of PPIS in acute non-variceal upper GL bleeds in a university teaching hospital. Gut. 67:A26.
   Web of Science ®Google Scholar
• Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, Leonardi S, Vranckx P, Windecker S, Valgimigli M. 2016. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J. 174:95–102.
   PubMed Web of Science ®Google Scholar
• Gaspar A, Ribeiro S, Nabais S, Rocha S, Azevedo P, Pereira MA, Brandāo A, Salgado A, Correia A. 2010. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol. 29:1511–1520.
   PubMedGoogle Scholar
• Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP. 2013. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 128:845–853.
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily J-C, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall J-F, Boschat J. 2008. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol. 51:256–260.
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. 2006. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 4:2508–2509.
   PubMed Web of Science ®Google Scholar
• Giraud MN, Sanduja SK, Felder TB, Illich PA, Dial EJ, Lichtenberger LM. 1997. Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther. 11:899–906.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. 2010. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 32:401–413.
   PubMed Web of Science ®Google Scholar
• Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, et al. 2012. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 125:978–986.
   PubMed Web of Science ®Google Scholar
• Gupta E, Bansal D, Sotos J, Olden K. 2010. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 55:1964–1968.
   PubMed Web of Science ®Google Scholar
• Haider F, Raza N, Komar N, Rahman O, Sartorius J, Kirchner HL. 2012. Proton pump inhibitor use elevates the risk of severe Clostridium difficile colitis. J Gastroenterol Hepatol Res. 1:53–56.
   Google Scholar
• Harjai KJ, Shenoy C, Orshaw P, Usmani S, Boura J, Mehta RH. 2011. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous an analysis from the guthrie health off-label stent (GHOST) investigators. Circ Cardiovasc Interv. 4:162–170.
   PubMed Web of Science ®Google Scholar
• Harrison RW, Mahaffey KW. 2012. Clopidogrel and PPI interaction: clinically relevant or not? Curr Cardiol Rep. 14:49–58.
   PubMed Web of Science ®Google Scholar
• Hasselgren G, Lundell L, Aadland E, Efskind P, Falk A, Hyltander A, Soderlund C, Eriksson S, Fernstrom P, Lind T. 1997. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol. 32:328–333.
   PubMed Web of Science ®Google Scholar
• Hawkey GM, Cole AT, Mcintyre AS, Long RG, Hawkey CJ, Alexandra Q, Wycombe H. 2001. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut. 49:372–379.
   PubMed Web of Science ®Google Scholar
• Health Canada. 2009. Potential interaction of Proton Pump Inhibitors (PPIs) with Plavix (clopidogrel) – For Health Professionals. 2017.
   Google Scholar
• Higgins J, Green S. 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
   Google Scholar
• Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. 2009. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc. 301:937–944.
   PubMed Web of Science ®Google Scholar
• Hokimoto S, Ogawa H. 2010. Is it safe to use a proton pump inhibitor with clopidogrel? A comparison of clopidogrel with or without rabeprazole in Japan. Gastroenterology. 138:S-498.
   Web of Science ®Google Scholar
• Hollander D, Dadufalza VD, Fairchild PA. 1981. Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med. 98:591–598.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lai KH, Liu CP. 2011. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 140:791–798.
   PubMed Web of Science ®Google Scholar
• Hudzik B, Szkodzinski J, Danikiewicz A, Wilczek K, Romanowski W, Lekston A, Polonski L, Zubelewicz-Szkodzinska B. 2010. Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Eur Cytokine Netw. 21:257–263.
   PubMed Web of Science ®Google Scholar
• Huang C-C, Chen Y-C, Leu H-B, Chen T-J, Lin S-J, Chan W-L, Chen J-W. 2010. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 105:1705–1709.
   PubMedGoogle Scholar
• Hung W-K, Li VKM, Chung C-K, Ying MWL, Loo C-K, Liu CKT, Lam BYK, Chan MCM. 2007. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. ANZ J Surg. 77:677–681.
   PubMed Web of Science ®Google Scholar
• Im JP, Cha JM, Kim JW, Kim SE, Ryu DY, Kim EY, Kim ER, Chang DK. 2014. Proton pump inhibitor use before percutaneous endoscopic gastrostomy is associated with adverse outcomes. Gut Liver. 8:248–253.
   PubMed Web of Science ®Google Scholar
• Iñarrea P, Esteva F, Cornudella R, Lanas A. 2000. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol. 35:242–246.
   PubMed Web of Science ®Google Scholar
• Javid G, Masoodi I, Zargar S, Khan B, Yatoo G, Shah A, Gulzar G, Sodhi J. 2001. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med. 111:280–284.
   PubMed Web of Science ®Google Scholar
• Joffe MM, Rosenbaum PR. 1999. Invited commentary: propensity scores. Am J Epidemiol. 150:327–333.
   PubMed Web of Science ®Google Scholar
• Johansson S, Wallander M, Ruigomez A, Garcia Rodriguez L. 2003. Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs? Aliment Pharmacol Ther. 18:973–978.
   PubMed Web of Science ®Google Scholar
• Juurlink DN. 2011. Clopidogrel with or without omeprazole in coronary disease. N Engl J Med. 364:681–682. Author reply 682–683.
   PubMedGoogle Scholar
• Juurlink DN, Dormuth CR, Huang A, Hellings C, Paterson JM, Raymond C, Kozyrskyj A, Moride Y, Macdonald EM, Mamdani MM. 2013. Proton pump inhibitors and the risk of adverse cardiac events. PLoS One. 8:e84890.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu J V, Henry DA, Kopp A, Mamdani MM. 2009. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 180:713–718.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Mamdani MM, Gladstone DJ, Kapral MK. 2011. The safety of proton pump inhibitors and clopidogrel in patients after stroke. Stroke. 42:128–132.
   PubMed Web of Science ®Google Scholar
• Kalantzi K, Tsoumani M, Goudevenos I, Tselepis A. 2012. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Rev Clin Pharmacol. 5:319–336.
   PubMed Web of Science ®Google Scholar
• Kantorova I, Svoboda P, Scheer P, Doubek J, Rehorkova D, Bosakova H, Ochmann J. 2004. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 51:757–761.
   PubMed Web of Science ®Google Scholar
• Kaviani M, Hashemi M, Kazemifar A, Roozitalab S, Mostaghni A, Merat S, Alizadeh-Naini M, Yarmohammadi H. 2003. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther. 17:211–216.
   PubMed Web of Science ®Google Scholar
• Keyvani L, Murthy S, Leeson S, Targownik LE. 2006. Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. Aliment Pharmacol Ther. 24:1247–1255.
   PubMed Web of Science ®Google Scholar
• Khuroo MS, Yattoo GN, Javid G, Khan BA, Shah AA, Gulzar GM, Sodi JS. 1997. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med. 336:1054–1058.
   PubMed Web of Science ®Google Scholar
• Kim M, Shin J, Jung S, Song H, Park B. 2014. Impact of concomitant use of proton pump inhibitors and dual antiplatelet therapy on recurrent myocardial infarction: a population-based case cross-over study. Pharmacoepidemiol Drug Saf. 23:456–457.
   PubMed Web of Science ®Google Scholar
• Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, Shizuta S, Shiomi H, Tada T, Tazaki J, et al. 2011. Association of the use of proton pump inhibitors with adverse cardiovascular and bleeding outcomes after percutaneous coronary intervention in the Japanese real world clinical practice. Cardiovasc Interv Ther. 26:222–233.
   PubMedGoogle Scholar
• Kip KE, Hollabaugh K, Marroquin OC, Williams DO. 2008. The problem with composite end points in cardiovascular studies. J Am Coll Cardiol. 51:701–707.
   PubMed Web of Science ®Google Scholar
• Krag M, Marker S, Perner A, Wetterslev J, Wise MP, Schefold JC, Keus F, Guttormsen AB, Bendel S, Borthwick M, et al. 2018. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med. 379:2199–2208. doi:10.1056/NEJMoa1714919.
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, et al. 2010. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 30:787–796.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Sung JJY, Barkun A, Mossner J, Jensen D, Stuart R, Lau JYW, Ahlbom H, Lind T, Kilhamn J. 2011. Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 28:150–159.
   PubMed Web of Science ®Google Scholar
• Kwok CS, Jeevanantham V, Dawn B, Loke YK. 2013. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 167:965–974.
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke D. 2010. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 31:810–823.
   PubMed Web of Science ®Google Scholar
• Kwon J, Koh S, Kim J, Lee K, Kim B. 2013. Proton pump inhibitors independently increase mortality in cirrhotic patients with spontaneous bacterial peritonitis. Gastroenterology. 144:S1014.
   Web of Science ®Google Scholar
• Kwon SH, Yoon JS, Lee JS, Kim HS, Lee YR, Kweon YO, Tak WY, Park SY, Jang SY, Wang SS, et al. 2016. Long-term proton pump inhibitor therapy improves survival in liver cirrhosis patients with variceal bleeding: a single center prospective study. Hepatology. 64:843A.
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, Lau GKK, Wong WM, Yuen MF, Chan AOO, et al. 2002. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 346:2033–2038.
   PubMed Web of Science ®Google Scholar
• Lau JY, Sung JJY, Lee KKC, Yung MY, Wong SKH. 2000. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 343:310–316.
   PubMed Web of Science ®Google Scholar
• Lau J, Leung W, Wu J, Chan FKL, Wong VWS, Chiu PWY, Lee VWY, Ph D, Lee KKC, Ph D, et al. 2007. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med. 356:1631–1640.
   PubMed Web of Science ®Google Scholar
• Lee S, Lien H, Chang C, Yeh H, Lee T, Tung C. 2015. The impact of acid-suppressing drugs to the patients with chronic obstructive pulmonary disease: a nationwide, population-based, cohort study. J Res Med Sci. 20:263–267.
   PubMed Web of Science ®Google Scholar
• Lei WY, Wang JH, Wen SH, Yi CH, Hung JS, Liu TT, Orr WC, Chen CL. 2017. Risk of acute myocardial infarction in patients with gastroesophageal reflux disease: a nationwide population-based study. PLoS ONE. 12:e0173899. doi:https://dx.doi.org/10.1371/journal.pone.0173899.
   PubMedGoogle Scholar
• Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, Bengtsson C, Björkelund C, Thelle D. 2008. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women. Arterioscler Thromb Vasc Biol. 28:961–967.
   PubMed Web of Science ®Google Scholar
• Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, et al. 2007. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 11:iii–126.
   Web of Science ®Google Scholar
• Leung WK, But DYK, Wong SY, Tong TSM, Liu KSH, Cheung KS, Tsang SHY, Chok KSH, Poon RTP, Hung IFN. 2018. Prevention of post-sphincterotomy bleeding by proton pump inhibitor: a randomized controlled trial. J Dig Dis. 19:369–376.
   PubMed Web of Science ®Google Scholar
• Liu B, Li B, Zhang X, Fei Z, Hu S, Lin W, Gao D, Zhang L. 2013. A randomized controlled study comparing omeprazole and cimetidine for the prophylaxis of stress-related upper gastrointestinal bleeding in patients with intracerebral hemorrhage. J Neurosurg. 118:115.
   PubMed Web of Science ®Google Scholar
• Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. 2017. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2:MR000033.
   PubMed Web of Science ®Google Scholar
• Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. 2012. Industry sponsorship and research outcome. In: Lundh A, editor. Cochrane database of systematic reviews, Vol. 12. Chichester (UK): John Wiley & Sons, Ltd.; p. MR000033.
   Google Scholar
• Mackenzie IS, Coughtrie MWH, MacDonald TM, Wei L. 2010. Antiplatelet drug interactions. J Intern Med. 268:516–529.
   PubMed Web of Science ®Google Scholar
• Maggio M, Corsonello A, Ceda G, Cattabiani C, Lauretani F, Butto V, Ferrucci L, Bandinelli S, Abbatecola A, Spazzafumo L. 2013. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 173:518–523.
   PubMed Web of Science ®Google Scholar
• Mahabaleshwarkar RK, Yang Y, Datar M V, Bentley JP, Strum MW, Banahan BF, Null KD. 2013. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients. Curr Med Res Opin. 29:315–323.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, et al. 2014. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One. 9:e110503.
   PubMed Web of Science ®Google Scholar
• Morgan CJ. 2018. Reducing bias using propensity score matching. J Nucl Cardiol. 25:404–406.
   PubMed Web of Science ®Google Scholar
• Munoz-Torrero JFS, Escudero D, Suarez C, Sanclemente C, Pascual MT, Zamorano J, Trujillo-Santos J, Monreal M. 2011. Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. J Cardiovasc Pharmacol. 57:13–19.
   PubMed Web of Science ®Google Scholar
• Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJP, McKeever TM. 2009. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf. 18:697–703.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. 2018. Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics. Hepatology. [Epub ahead of print]
   Web of Science ®Google Scholar
• Nguyen LH, Lochhead P, Joshi AD, Cao Y, Ma W, Khalili H, Rimm EB, Rexrode KM, Chan AT. 2018. No significant association between proton pump inhibitor use and risk of stroke after adjustment for lifestyle factors and indication. Gastroenterology. 154:1290–1297.e1.
   PubMed Web of Science ®Google Scholar
• Nikcevic G, Raspopovic S, Pejic M, Srdic M, Djordjevic S, Milosevic GV, Tomic M, Kostic J, Vasiljevic Z, Milasinovic G, S R. 2011. Prognostic implications of acute gastrointestinal bleeding in acute coronary syndrome: intrahospital follow up. Eur Heart J. 32:100.
   Web of Science ®Google Scholar
• Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, Yin X, Hou Y. 2016. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 22:142–152. doi:10.1177/1074248416663647
   PubMed Web of Science ®Google Scholar
• Norgard NB, DiNicolantonio JJ. 2013. Clopidogrel, Prasugrel, or Ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med. 125:91–102.
   PubMed Web of Science ®Google Scholar
• O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, et al. 2009. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 374:989–997.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Echizen H. 2010. Drug–drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 49:509–533.
   PubMed Web of Science ®Google Scholar
• Ortolani P, Marino M, Marzocchi A, De Palma R, Branzi A. 2012. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. J Cardiovasc Med. 13:783–789.
   Google Scholar
• Oudit GY, Bakal JA, McAlister FA, Ezekowitz JA. 2011. Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. Eur J Heart Fail. 13:1211–1215.
   PubMed Web of Science ®Google Scholar
• Owen C, Marks DJB, Banks M. 2014. The dangers of proton pump inhibitor therapy. Br J Hosp Med (Lond). 75:C108–C112.
   PubMed Web of Science ®Google Scholar
• Pattanayak CW, Rubin DB, Zell ER. 2011. Métodos de puntuación de propensión para crear una distribución equilibrada de las covariables en los estudios observacionales. Rev Española Cardiol. 64:897–903.
   PubMed Web of Science ®Google Scholar
• Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. 2009. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 120:2322–2329.
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM. 2010. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 152:337–345.
   PubMed Web of Science ®Google Scholar
• Reimer C. 2013. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 27:443–454.
   PubMed Web of Science ®Google Scholar
• Rochette L, Lorin J, Zeller M, Guilland J-C, Lorgis L, Cottin Y, Vergely C. 2013. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther. 140:239–257.
   PubMed Web of Science ®Google Scholar
• Rossini R, Capodanno D, Musumeci G, Lettieri C, Lortkipanidze N, Romano M, Nijaradze T, Tarantini G, Cicorella N, Sirbu V, et al. 2011. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis. 22:199–205.
   PubMed Web of Science ®Google Scholar
• Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, Mehilli J, Schomig A, Kastrati A. 2010. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost. 104:626–632.
   PubMed Web of Science ®Google Scholar
• Schaffalitzky de Muckadell OB, Havelund T, Harling H, Boesby S, Snel P, Vreeburg EM, Eriksson S, Fernstrom P, Hasselgren G. 1997. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol. 32:320–327.
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Naucler E, Svedberg LE. 2011. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 97:797–802.
   PubMed Web of Science ®Google Scholar
• Schillinger W, Hörnes N, Teucher N, Sossalla S, Sehrt D, Jung K, Hünlich M, Unsöld B, Geiling B, Ramadori G, et al. 2009. Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers. Clin Res Cardiol. 98:391–399.
   PubMed Web of Science ®Google Scholar
• Schillinger W, Teucher N, Sossalla S, Kettlewell S, Werner C, Raddatz D, Elgner A, Tenderich G, Pieske B, Ramadori G, et al. 2007. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation. 116:57–66.
   PubMed Web of Science ®Google Scholar
• Schnoll-Sussman F, Katz PO. 2017. Clinical implications of emerging data on the safety of proton pump inhibitors. Curr Treat Options Gastroenterol. 15:1–9.
   PubMedGoogle Scholar
• Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W-D, Lieb K. 2010. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int. 107:279–285.
   PubMed Web of Science ®Google Scholar
• Seeger JD, Kurth T, Walker AM. 2007. Use of propensity score technique to account for exposure-related covariates. Med Care. 45:S143–S148.
   PubMed Web of Science ®Google Scholar
• Sehested TSG, Gerds TA, Fosbol EL, Hansen PW, Charlot MG, Carlson N, Hlatky MA, Torp-Pedersen C, Gislason GH. 2018. Long-term use of proton pump inhibitors, dose–response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 283:268–281.
   PubMed Web of Science ®Google Scholar
• Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM. 2016. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med. 44:1842–1850.
   PubMed Web of Science ®Google Scholar
• Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, Nead KT, Cooke JP, Leeper NJ. 2015. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 10:e0124653.
   PubMed Web of Science ®Google Scholar
• Shih C-J, Chen Y-T, Ou S-M, Li S-Y, Chen T-J, Wang S-J. 2014. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 177:292–297.
   PubMed Web of Science ®Google Scholar
• Shiraev TP, Bullen A. 2018. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 27:443–450.
   PubMed Web of Science ®Google Scholar
• SIGN. n. d. Search filters. [accessed 2015 Nov 8]. http://www.sign.ac.uk/methodology/filters.html.
   Google Scholar
• Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. 2010. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 8:2624–2641.
   PubMed Web of Science ®Google Scholar
• Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefevre T, Drouet E, et al. 2011. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocard. Circulation. 123:474–482.
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ. 2008. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 48:475–484.
   PubMed Web of Science ®Google Scholar
• Sofia C, Portela F, Gregorio C, Rosa A, Camacho E, Tome L, Ferreira M, Andrade P, Cabral P, Romaozinho J, et al. 2000. Endoscopic injection therapy vs. multipolar electrocoagulation vs. laser vs. injection + octreotide vs. injection + omeprazole in the treatment of bleeding peptic ulcers. A prospective randomized study. Hepatogastroenterology. 47:1332–1336.
   PubMedGoogle Scholar
• Stockl KM, Le L, Zakharyan A, Harada ASM, Solow BK, Addiego JE, Ramsey S. 2010. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 170:704–710.
   PubMed Web of Science ®Google Scholar
• Strom B, Kimmel S, Madre L, Califf R, Reynolds R, Arlett P, Moseley J, 2006. Textbook of pharmacoepidemiology. West Sussex, UK: John Wiley and Sons Inc.; p. 71.
   Google Scholar
• Sugano K, Choi M, Lin J, Goto S, Okada Y, Kinoshita Y, Miwa H, Chiang C, Chiba T, Hori M, et al. 2014. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 63:1061–1068.
   PubMed Web of Science ®Google Scholar
• Sung JJY, Barkun A, Kuipers EJ, Mossner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T, et al. 2009. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 150:455–464.
   PubMed Web of Science ®Google Scholar
• Sweeny J, Kini A, Muntner P, Jakkula M, Farkouh M, Sharma S. 2009. Mortality associated with proton pump inhibitors following percutaneous coronary interventions with drug eluting stents. Circulation. 120:S936.
   Web of Science ®Google Scholar
• Symons MJ, Moore DT. 2002. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol. 55:893–899.
   PubMed Web of Science ®Google Scholar
• Taha A, Saffouri E, McCloskey C, Craigen T, Angerson W. 2013. Pre-endoscopic intravenous proton pump inhibition and the outcomes of acute upper gastrointestinal bleeding. Gastroenterology. 144:S211.
   PubMed Web of Science ®Google Scholar
• Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-Matula J, Huber K. 2010. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 104:1211–1218.
   PubMed Web of Science ®Google Scholar
• Teramura-Gronblad M, Bell JS, Poysti MM, Strandberg TE, Laurila JV, Tilvis RS, Soini H, Pitkala KH. 2012. Risk of death associated with use of PPIs in three cohorts of institutionalized older people in Finland. J Am Med Dir Assoc. 13:488.e9–413.
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration. 2014. Review Manager (RevMan).
   Google Scholar
• Turkiewicz A, Vicente RP, Ohlsson H, Tyden P, Merlo J. 2015. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction-a case-crossover analysis. Eur J Clin Pharmacol. 71:125–129.
   PubMed Web of Science ®Google Scholar
• Ulhaq I, Sood R, Hegade V, Moreea S, Bulugahapitiya S. 2011. Response to clopidogrel with proton pump inhibitors: safe or not? -Letter to the editor. Clin Cardiol. 34:721.
   PubMedGoogle Scholar
• Valkhoff VE, ‘t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MCJM. 2011. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 33:77–88.
   PubMed Web of Science ®Google Scholar
• van Boxel OS, van Oijen MGH, Hagenaars MP, Smout AJPM, Siersema PD. 2010. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large dutch cohort study. Am J Gastroenterol. 105:2430–2436.
   PubMed Web of Science ®Google Scholar
• van der Hoorn M, Tett S, de Vries O, Dobson A, Peeters G. 2015. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone 81:675–682.
   PubMed Web of Science ®Google Scholar
• Wang Q, Ljung R, Lagergren J, Lu Y. 2014. Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding. BMC Pharmacol Toxicol. 15:22.
   PubMed Web of Science ®Google Scholar
• Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ. 2017. Proton-Pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 112:1084–1093.
   PubMed Web of Science ®Google Scholar
• Wei KL, Tung SY, Sheen CH, Chang TS, Lee IL, Wu CS. 2007. Effect of oral esomeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. J Gastroenterol. Hepatol. 22:43–46.
   PubMed Web of Science ®Google Scholar
• Weisz G, Smilowitz NR, Kirtane AJ, Rinaldi MJ, Parvataneni R, Xu K, Stuckey TD, Maehara A, Witzenbichler B, Neumann FJ, et al. 2015. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: the ADAPT-DES Study. Circ Cardiovasc Interv. 8:1–8.
   Web of Science ®Google Scholar
• Wells G, Shea B, O’Connel D, Peterson J, Welch V, Losos M, Tugwell P. 2008. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [accessed 2016 Feb 20]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Whellan D, Goldstein J, Cryer B, Eisen G, Lanas A, Miller A, Scheiman J, Fort J, Zhang Y, O’Connor C. 2014. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. Am Heart J. 168:495.
   PubMed Web of Science ®Google Scholar
• Win M, Joseph J, Gress F, Lee Y, Goodman A. 2010. Effect of baseline Proton Pump Inhibitor (PPI) use on the prevalence and outcomes of peptic ulcer disease in African American patients with overt Upper Gastrointestinal Bleeding (UGIB). Am J Gastroenterol. 105:S526–S527.
   Web of Science ®Google Scholar
• Wu H, Wang J, Guo X, Jing Q. 2011. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J Crit Care. 26:434.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Chan FK-L, Wu M-S, Kuo KN, Wang C-B, Tsao C-R, Lin J-T. 2010. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 139:1165–1171.
   PubMed Web of Science ®Google Scholar
• Würtz M, Grove EL. 2017. Proton pump inhibitors in cardiovascular disease: drug interactions with antiplatelet drugs. Adv Exp Med Biol. 906:325–350. doi:10.1007/5584_2016_124
   PubMed Web of Science ®Google Scholar
• Würtz M, Grove EL, Kristensen SD, Hvas A-M. 2010. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart. 96:368–371.
   PubMed Web of Science ®Google Scholar
• Yan Y, Wang X, Fan J-Y, Nie S-P, Raposeiras-Roubín S, Abu-Assi E, Henriques JPS, D'Ascenzo F, Saucedo J, González-Juanatey JR, et al. 2016. Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome. J Geriatr Cardiol. 13:209–217.
   PubMedGoogle Scholar
• Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Racz I, Tchernev K, Karamanolis D, Roda E, Hawkey C, et al. 2008. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 103:2465–2473.
   PubMed Web of Science ®Google Scholar
• Yi X, Han Z, Zhou Q, Cheng W, Lin J, Wang C. 2018. Concomitant use of proton-pump inhibitors and clopidogrel increases the risk of adverse outcomes in patients with ischemic stroke carrying reduced-function CYP2C19 2. Clin Appl Thromb Hemost. 24:55–62.
   PubMed Web of Science ®Google Scholar
• Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. 2016. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis. Dig Liver Dis. 48:353–359.
   PubMedGoogle Scholar
• Zairis MN, Tsiaousis GZ, Patsourakos NG, Georgilas AT, Kontos CF, Adamopoulou EN, Vogiatzidis K, Argyrakis SK, Fakiolas CN, Foussas SG. 2010. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 26:e54–e57.
   PubMed Web of Science ®Google Scholar
• Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM, Sodhi JS, Mujeeb SA, Khan MA, Shah NA, et al. 2006. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. J Gastroenterol Hepatol. 21:716–721.
   PubMed Web of Science ®Google Scholar
• Zou J-J, Chen S-L, Tan J, Lin L, Zhao Y-Y, Xu H-M, Lin S, Zhang J, Fan H-W, Xie H-G. 2014. Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor. PLoS One. 9:e84985.
   PubMed Web of Science ®Google Scholar